Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospects.
antibody engineering
antibody libraries
biologics discovery technologies
developability screening
functional screening
genetic engineering
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
23
07
2024
accepted:
04
09
2024
medline:
9
10
2024
pubmed:
9
10
2024
entrez:
9
10
2024
Statut:
epublish
Résumé
The evolving development landscape of biotherapeutics and their growing complexity from simple antibodies into bi- and multi-specific molecules necessitates sophisticated discovery and engineering platforms. This review focuses on mammalian display technology as a potential solution to the pressing challenges in biotherapeutic development. We provide a comparative analysis with established methodologies, highlighting key aspects of mammalian display technology, including genetic engineering, construction of display libraries, and its pivotal role in hit selection and/or developability engineering. The review delves into the mechanisms underpinning developability-driven selection via mammalian display and their broader implications. Applications beyond antibody discovery are also explored, alongside advancements towards function-first screening technologies, precision genome engineering and AI/ML-enhanced libraries, situating them in the context of mammalian display. Overall, the review provides a comprehensive overview of the current mammalian display technology landscape, underscores the expansive potential of the technology for biotherapeutic development, addresses the critical challenges for the full realisation of this potential, and examines advances in related disciplines that might impact the future application of mammalian display technologies.
Identifiants
pubmed: 39381002
doi: 10.3389/fimmu.2024.1469329
pmc: PMC11459229
doi:
Substances chimiques
Antibodies, Monoclonal
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1469329Informations de copyright
Copyright © 2024 Slavny, Hegde, Doerner, Parthiban, McCafferty, Zielonka and Hoet.
Déclaration de conflit d'intérêts
PS, MH, KP, and RH are affiliated with Iontas/FairJourney Biologics. AD and SZ are affiliated with Merck Healthcare KGaA and may hold its shares. JM is the co-founder of Iontas and inventor of the Iontas Proprietary mammalian display technology and is currently affiliated with Maxion® Therapeutics. Iontas/FairJourney Biologics holds intellectual property in mammalian display technology and offers antibody discovery and engineering services.